Search

Search Constraints

You searched for: Author/Creator Macaluso, F.S.

Search Results

1. AF.124 EFFECTIVENESS AND SAFETY OF 1L PEG-ASC PREPARATION FOR COLONOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. (September 2021)

2. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021)

3. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021)

4. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. Issue 9 (September 2021)

6. OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD). (May 2022)

7. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020)

8. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety. (15th March 2017)

9. OC.06.4: The Addition of an Immunosuppressant is an Effective Optimization Strategy after Loss of Response to Anti-Tnf Alpha Monotherapy in Patients with Inflammatory Bowel Disease: A Two-Year Experience. (15th March 2017)

10. OC.06.5: Mycophenolate Mofetil is a Valid Option in Patients with Inflammatory Bowel Disease Resistant to TNF-Alpha Inhibitors and Conventional Immunosuppressants. (15th March 2017)